Stock events for STERIS Plc (Ireland) (STE)
STERIS Plc's stock has been influenced by several events in the past six months. The Q3 Fiscal 2026 Earnings Report showed adjusted EPS meeting expectations and revenue growth, but the stock price declined due to reaffirmed full-year guidance and raised tariff expectations. The company held its Q2 fiscal 2026 earnings conference call on November 6, 2025. Institutional trading activity has been mixed, with some firms trimming stakes and others increasing positions. STERIS completed a US$350.6 million share repurchase program and announced a dividend of $0.63 per share.
Demand Seasonality affecting STERIS Plc (Ireland)’s stock price
While demand for STERIS's products and services is generally stable, there is some indication of seasonality. Analysts have noted potential fluctuations in demand during the company's fourth fiscal quarter (January-March). However, the underlying need for sterilization and decontamination drives consistent demand for STERIS's offerings.
Overview of STERIS Plc (Ireland)’s business
STERIS Plc is an American-Irish medical technology company specializing in infection prevention and procedural products and services. It is legally registered in Dublin, Ireland, but its operational headquarters are in Mentor, Ohio, U.S. STERIS operates in the healthcare sector, focusing on medical devices, and aims to create a healthier and safer world through innovative solutions. The company's business is divided into three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences, each offering specific products and services to healthcare providers, medical device and pharmaceutical manufacturers, and biopharmaceutical research facilities.
STE’s Geographic footprint
STERIS Plc has a global presence, operating in over 100 countries. While legally registered in Dublin, Ireland, its operational headquarters are in Mentor, Ohio, U.S. The United States accounts for 73.4% of its net sales, with other locations contributing 24.6% and Ireland 2%. The company has manufacturing facilities and service centers across North America, Europe, and Asia.
STE Corporate Image Assessment
STERIS Plc maintains a strong brand reputation based on its mission to promote a healthier and safer world through infection prevention and procedural products and services. The company's focus on patient safety and regulatory compliance reinforces its market leadership. Consistent financial performance and strategic acquisitions have solidified its position in high-growth infection prevention markets.
Ownership
STERIS Plc is primarily owned by institutional investors, holding 94.69% of the company's shares. Major institutional owners include Vanguard Group Inc., BlackRock Inc., and Massachusetts Financial Services Co (MFS). Individual investors hold approximately 5.3% of the remaining shares.
